| STATE STREET EMERGING MARKETS OPPORTUNITIES EQUITY FUND P EUR CAP | RVI EMERGENTES | 45,89% | 83,40% | · | · |
| FRANKLIN GENOMIC ADVANCEMENTS I (ACC) EUR | RVI BIOTECNOLOGÍA | 45,88% | 32,24% | · | · |
| ABRDN SICAV I-EMERGING MARKETS EQUITY FUND A ACC EUR | RVI EMERGENTES | 45,87% | 70,64% | 31,07% | 84,98% |
| DWS INVEST ENHANCED COMMODITY STRATEGY JPY JC | RVI MATERIAS PRIMAS | 45,86% | 41,64% | 73,67% | · |
| MSIF CALVERT SUSTAINABLE EMERGING MARKETS EQUITY SELECT A (USD) | RVI EMERGENTES | 45,83% | 78,35% | · | · |
| FRANKLIN GENOMIC ADVANCEMENTS W (ACC) USD | RVI BIOTECNOLOGÍA | 45,81% | 32,03% | · | · |
| M&G (LUX) JAPAN SMALLER COMPANIES FUND EUR A-H ACC | RVI JAPÓN SMALL/MID CAP | 45,81% | 90,90% | 165,56% | · |
| BNP PARIBAS JAPAN SMALL CAP PRIVILEGE H EUR CAP | RVI JAPÓN SMALL/MID CAP | 45,80% | 132,88% | 176,38% | 396,46% |
| CANDRIAM EQUITIES L EMERGING MARKETS I-H CAP USD | RVI EMERGENTES | 45,80% | · | · | · |
| CT (LUX) RESPONSIBLE GLOBAL EMERGING MARKETS EQUITY R EUR ACC | RVI EMERGENTES | 45,80% | 72,34% | 44,93% | · |
